Breast Cancer Clinical Trials in La Jolla, California

15 studies are recruiting for breast cancer in La Jolla, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    University of San Diego Moores Cancer Center, La Jolla, California
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UC San Diego Moores Cancer Center, La Jolla, California
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  3. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UC San Diego Moores Cancer Center, La Jolla, California
    Locations
    64 in total
    Run by
    Genentech, Inc.

    See if you can join NCT07100106 on ClinicalTrials.gov

  4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participants with endocrine-sensitive PIK3CA-mutated hormone receptor-p…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Scripps Health, La Jolla, California
    Locations
    241 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT06790693 on ClinicalTrials.gov

  5. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    UC San Diego Moores Cancer Center, La Jolla, California
    Locations
    5 in total
    Run by
    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

  6. A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer

    This study is aimed to establish a registry of women undergoing intensive surveillance for the early detection of breast cancer in high-risk women.

    Stage
    Not phased
    Ages
    25 and older
    Site
    University of California, San Diego, La Jolla, California
    Locations
    3 in total
    Run by
    University of Chicago

    See if you can join NCT03729115 on ClinicalTrials.gov

  7. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, La Jolla, California
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  8. FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of California, San Diego, La Jolla, California
    Locations
    8 in total
    Run by
    Regor Pharmaceuticals Inc.

    See if you can join NCT05304962 on ClinicalTrials.gov

  9. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    University of California San Diego - Moores Cancer Center, La Jolla, California
    Locations
    179 in total
    Run by
    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

  10. Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #101, La Jolla, California
    Locations
    18 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06545942 on ClinicalTrials.gov

  11. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California San Diego, La Jolla, California
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  12. Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

    The goal of this clinical trial is to learn if an artificial intelligence model will be able to select patients with advanced breast cancer who may respond to a second cyclin-dependent kinase 4/6 (CDK4/6) inhibitor after they have progressed on the first CDK4/6 inhibitor. Patients for this study ne…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of California, San Diego, La Jolla, California
    Run by
    University of California, San Diego

    See if you can join NCT07227233 on ClinicalTrials.gov

  13. A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

    This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The st…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, La Jolla, California
    Locations
    7 in total
    Run by
    Hummingbird Bioscience

    See if you can join NCT06956690 on ClinicalTrials.gov

  14. Efficacy of OneMark Device in Identifying Breast Cancer for Surgery and Surveillance

    The goal of this research is to study a localization device for breast cancer called OneMark. This device will be studied in breast cancer surgery and during surveillance in patients being monitored for breast cancer. The main questions the study aims to answer are: Can surgeons visualize the OneMa…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of California, San Diego, La Jolla, California
    Run by
    University of California, San Diego

    See if you can join NCT07087691 on ClinicalTrials.gov

  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, La Jolla, California
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.